Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 19, ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable healthcare stocks to buy now. Gilead Sciences, Inc. (NASDAQ ...
Zacks Investment Research on MSN
Why Gilead Sciences (GILD) dipped more than broader market today
In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.14%. Elsewhere, ...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the June 2027 expiration. One of the key data points that goes into the price an option buyer is willing to ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.
Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, ...
Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the treatment of HIV met the primary endpoint in the late-stage ARTISTRY-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback